tranScrip logo — tranScrip is now part of TMC, a global pharma services compa...

tranScrip

tranScrip is now part of TMC, a global pharma services company offering end-to-end drug development solutions

Founded 2008 United Kingdom Wokingham, United Kingdom 68 employees Growth Biotechnology, Health Care +1

General Information

Company Name tranScrip
Founded Year 2008
Location United Kingdom Wokingham, United Kingdom
Employees 68
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Growth
Business Model B2B, B2D, B2B2B
Revenue Model Service Fee, Consulting Fee, Project Based
Social

BounceWatch is an independent company data service, not affiliated with tranScrip. To contact tranScrip, visit transcrip-group.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does tranScrip compare?

A PDF of tranScrip and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting tranScrip soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About tranScrip

tranScrip is a specialist consultancy firm based in the United Kingdom focused on the pharmaceutical industry. Founded in 2008, it provides a comprehensive suite of services spanning strategic insights, therapeutic expertise, and operational support throughout a product's lifecycle.

With a clear slogan, "A specialist pharmaceutical consultancy providing strategic, therapeutic and operational services across the lifecycle," the company is committed to maximizing product value through tailor-made solutions. Its team is composed of experienced physicians, scientists, and regulatory, clinical, and commercial experts, emphasizing flexibility and bespoke approaches to expedite development and commercialization, ultimately benefiting patients worldwide.

The company's strategic importance in the Biotechnology, Health Care, and Pharmaceutical industries is underscored by its recent funding. On 01 January 2021, tranScrip received a Growth Equity VC investment from Palatine, which will likely fuel further innovation and expansion.

Business keywords: Strategic Expertise, Therapeutic Experience, Operational Excellence, Product Lifecycle Management, Regulatory Affairs, Clinical Development, Commercialisation Strategy, Drug Safety, Pharmacovigilance, Medical Affairs, Oncology, Infectious Diseases, CNS & Pain, Respiratory Medicine

Services & Products

Fractional Chief Medical Officer
Regulatory Affairs
Clinical Development
Pharmacovigilance & Risk Management
Commercialisation
Medical Affairs

Target Customers

Pharmaceutical Companies Biotech Companies

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Growth Equity VC Undisclosed 1
Palatine
01 Jan 2021

tranScrip Alternatives & Competitors

View All Alternatives
tranScrip vs

Your strategic partner in advancing patient health

Private Equity
81 employees
Biotechnology, Health Care
tranScrip vs

Streamline & Accelerate Cross-border Clinical Trial Pathways

Series A
108 employees
Biopharma, Biotechnology
tranScrip vs
Simbec-Orion
Simbec-Orion United Kingdom

Flexible, high-quality, Phase I - IV clinical trial solutions, delivered with integrity.

306 employees
Biotechnology, Pharmaceutical

FAQ About tranScrip

tranScrip is now part of TMC, a global pharma services company offering end-to-end drug development solutions
tranScrip was founded in 2008.
tranScrip is headquartered in Wokingham, United Kingdom.
tranScrip operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Strategic Expertise, Therapeutic Experience, Operational Excellence and Product Lifecycle Management. Its customers include Pharmaceutical Companies and Biotech Companies.
tranScrip has a B2B, B2D and B2B2B business model. Its revenue comes from Service Fee, Consulting Fee and Project Based.
tranScrip has approximately 68 employees.
tranScrip has completed 1 funding round. The latest funding stage is Growth.
tranScrip offers: Fractional Chief Medical Officer, Regulatory Affairs, Clinical Development, Pharmacovigilance & Risk Management, Commercialisation, Medical Affairs.
Top alternatives and competitors to tranScrip include TMC Pharma Services Ltd, HiRO - Harvest Integrated Research Organization, Simbec-Orion, Global Clinical Trials (GCT), Moderna. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
tranScrip and TMC Pharma Services Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for tranScrip, https://bouncewatch.com/company/transcrip, updated 26 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes